International Travel Patterns and Risk Behaviour of Breast Cancer, Lymphoma Patients and Bone Marrow Transplant Recipients
May 30, 2012 updated by: Memorial Sloan Kettering Cancer Center
Pilot Survey to Assess International Travel Patterns and Risk Behaviour of Breast Cancer, Lymphoma Patients and Bone Marrow Transplant Recipients at Memorial Sloan-Kettering Cancer Center
This study also aims to raise awareness among both patients and health-care providers about the importance of pre-travel health consultation and preventive interventions prior to international travel.
Through appropriate health counseling, cancer patients will have less risk of having travel -related health complications and thus have a better quality of life and overall improved sense of wellbeing.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
26
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
The goal accrual is 50 patients from each of the following oncology services:
Breast, Lymphoma, Autologous Stem Cell Transplant, and Allogeneic Stem Cell Transplant.
Description
Inclusion Criteria:
- Hematopoietic Stem Cell Transplant (HSCT) recipients
- Age >18 years
- Status post bone marrow transplant within last five years Breast Cancer patients: Criteria 1 and Criteria 2 and/or 3
- Female age >18 years and current or past history of breast cancer
- Received systemic chemotherapy in the last five years
- Metastatic breast cancer disease (stage IV) Lymphoma: Criteria 1 and Criteria 2 and/or 3
- Age >18 years and current or past history of lymphoma
- Received systemic chemotherapy within 5 years
- Had active disease at any time within the last 5 years
Exclusion Criteria:
- Patients age< 18 years
- Breast cancer and lymphoma patients in clinical remission in the past 5 years
- Patients unable to fill the questionnaire due to language barriers
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
questionnaires
There will be four versions of the questionnaire, each slightly modified to be more specific toward the treatment paradigms in the respective target patient population (Breast Cancer/ Lymphoma/Autologous Bone Marrow Transplant/ Allogeneic Bone Marrow Transplant).
All questionnaire versions will consist of seven sections.
|
The intervention is a self-administered anonymous questionnaire that is voluntarily completed by the patient.
Questions in Section One will cover general information about the patient including gender, age, race, country of birth, current zip code of residence, and level of education.
Questions in Section Two will cover information regarding the cancer (breast/lymphoma) or transplant (allogeneic/ autologous).
Questions in Section Three will cover travel history including the frequency of travel outside the United States and Canada in the last 5 years.
Questions in Sections Four through Seven will obtain information about their last trip outside the United States and Canada.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To determine the frequency of international travel of the targeted patients in the last 5 years.
Time Frame: once at the time of the clinic visit
|
once at the time of the clinic visit
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To determine if any of the international travel was during a high-risk specific period when the immune status of the target population was compromised.
Time Frame: once at the time of the clinic visit
|
once at the time of the clinic visit
|
|
To profile the target population who traveled internationally with respect to their demographic and cancer/transplant-related characteristics.
Time Frame: once at the time of the clinic visit
|
once at the time of the clinic visit
|
|
To obtain detailed information about their last international trip including
Time Frame: once at the time of the clinic visit
|
once at the time of the clinic visit
|
|
To assess the adequacy of the questionnaire instructions
Time Frame: once at the time of the clinic visit
|
once at the time of the clinic visit
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Monika Shah, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2010
Primary Completion (Actual)
March 1, 2012
Study Completion (Actual)
March 1, 2012
Study Registration Dates
First Submitted
April 22, 2010
First Submitted That Met QC Criteria
April 26, 2010
First Posted (Estimate)
April 27, 2010
Study Record Updates
Last Update Posted (Estimate)
June 1, 2012
Last Update Submitted That Met QC Criteria
May 30, 2012
Last Verified
May 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10-045
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.